Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection

Nakamura, Yuki; Aikata, Hiroshi; Fukuhara, Toru; Honda, Fumi; Morio, Kei; Morio, Reona; Hatooka, Masahiro; Kobayashi, Tomoki; Nagaoki, Yuko; Tsuge, Masataka; Hiramatsu, Akira; Kawakami, Yoshiiku; Ochi, Hidenori; Kobayashi, Tsuyoshi; Ohdan, Hideki; Shiroma, Noriyuki; Arihiro, Koji; Chayama, Kazuaki

doi:10.1111/hepr.12815

Cited by 20 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The procedure is invasive and painful, with the risk of rare but potential life-threatening complications [12] FibroScan is a non-invasive test that assesses stiffness in the liver [13] . Its results had good correlation with the histology of liver fibrosis in patients with hepatitis C [14] . However, measurements can be difficult to obtain in obese patients or in those who have narrow intercostal spaces, and is impossible to achieve in patients with ascites [15] .…”

Section: Introductionmentioning

confidence: 72%

Estimation of Serum Interleukin-18 in Hepatitis C Patients in Zagazig University Hospitals

El-Amin¹,

Elkhashab²,

Ibrahim³

et al. 2019

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: HCV is a contagious blood-borne virus that attacks the liver and can be deadly despite often having no visible health warnings. IL-18 is an important proinflammatory cytokine secreted from Kupffer cells. It is involved in the pathogenesis of HCV infection through modulating immune functions by regulating IFN-γ production and promoting the development of Th1 immune responses. Objective: The aim of this study is to measure serum level of Il-18 in chronic hepatitis C patients and compare between Il-18 levels and the degree of liver fibrosis. Subjects & Methods: This is a case control study. It was conducted in Clinical Pathology and Tropical Medicine Departments, Faculty of Medicine, Zagazig University Hospitals during the period from June 2017 to August 2017. Eighty four subjects were included in this study; they were classified into three groups as follows: Group 1: composed of 28 (17 males,11 females) apparently healthy subjects their ages ranged from 27 to 61 years old. Group 2 :composed of 28 patients (15 males,13 females) with HCV infection diagnosed as HCV RNA positive serum by RT-PCR with normal liver enzymes(ALT,AST), their ages ranged from 25 to 63 years old. Group 3 :composed of 28 patients (16 males,12 females) with HCV infection diagnosed as HCV RNA positive serum by RT-PCR with elevated liver enzymes (ALT,AST) their ages ranged from 29 to 64 years old. Formal consent was obtained from all individual and the study protocol was approved by the Zagazig medical research ethical committee. Seven ml of venous blood was withdrawn by sterile venipuncture and used for routine investigations including, complete liver function tests, HCV antibodies by ELISA and HCV-RNA by RT-PCR and IL-18 serum level by ELISA technique. Results: Group III showed highly statistically significant increased ALT and AST when compared to both group I and group II. There were high statistical significant differences between the three studied groups as regard Albumin level, Prothrombin time, Concentration (%) and INR. There was statistical significant increase in viral load by PCR in Group III compared to Group II. There were high statistical significant differences between Group III compared to both Group I and Group II in IL-18 level. there were statistical significance increase in IL-18 level with increase degree of liver fibrosis in both Group II & Group III. There was positive significant correlation between IL-18 level and AST in Group III. There was positive high significant correlation between IL-18 level and viral load in Group III. Conclusion: Serum IL-18 is significantly increase in chronic HCV patients and is correlated with liver fibrosis staging determined by fibroscan. So, IL-18 can be used as a non-invasive pro inflammatory marker for detection of the chronicity and severity of liver fibrosis in CHC.

show abstract

Section: Introductionmentioning

confidence: 72%

Estimation of Serum Interleukin-18 in Hepatitis C Patients in Zagazig University Hospitals

El-Amin¹,

Elkhashab²,

Ibrahim³

et al. 2019

Zagazig University Medical Journal

View full text Add to dashboard Cite

show abstract

“…Liver stiffness assessed by FibroScan was compared with liver fibrosis of resected liver sections quantified with METAVIR system. A positive correlation (P ≤ 0.0001) was observed between them in a group of patients with chronic HCV infection and liver tumor, so that FibroScan can be used for non-invasive staging of hepatic fibrosis [27].…”

Section: Could Liver Fibrosis Presence and Severity Be Assessed By LImentioning

confidence: 88%

Liver stiffness in chronic hepatitis C virus infection

Mihăilă

2019

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

Introduction. The severity of liver fibrosis can be assessed noninvasively today by liver stiffness measurements. Vibration-controlled transient elastography, shear wave elastography or magnetic resonance elastography are techniques increasingly used for this purpose. Methods. This article presents the recent advances in the use of new techniques for liver fibrosis assessment in chronic hepatitis C: the correlation between liver stiffness values and liver fibrosis estimated by liver biopsies, the prognosis role of liver stiffness values, their usefulness in monitoring the treatment response, in assessing the severity of portal hypertension and in estimating the presence of esophageal varices. Scientific articles from January 2017 to January 2018 were searched in PubMed and PubMed Central databases, using the terms “liver stiffness” and “hepatitis C”. Results. The median liver stiffness values measured with different techniques are not identical, so that FibroScan thresholds cannot be used on any other elastographic machine. The higher the liver’s stiffness measurement, the higher the liver-related events in patients with chronic hepatitis C. A liver stiffness measurement over 17 kPa could be an independent predictor for the presence of esophageal varices as well as a spleen with a longitudinal span ≥ 15 cm for patients with a value of liver stiffness < 17 kPa. A progressive and persistent decrease in liver stiffness is dependent on sustained virological response achievement. The lack of liver stiffness decrease has been associated with relapsers and a low value of liver stiffness at baseline. Conclusion. Liver stiffness provides clues about the severity and evolution of liver disease.

show abstract

“…The development of transient elastography using FibroScan (Echosens, Paris, France) made it possible to quantitate liver elasticity non‐invasively. The diagnostic accuracy of FibroScan for liver fibrosis has been widely recognized for various chronic liver diseases, and liver stiffness measurement (LSM) at baseline has been shown as the independent factor of HCC occurrence in chronic hepatitis C patients …”

Section: Introductionmentioning

confidence: 99%

Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C

Ogasawara

Saitoh

Akuta

et al. 2020

Hepatology Research

View full text Add to dashboard Cite

Aim: The risk of development of hepatocellular carcinoma (HCC) persisted in patients with advanced fibrosis, even after achieving sustained virologic response (SVR). This study aimed to show the advantage of liver stiffness measurement (LSM) at baseline and after SVR to predict HCC occurrence and esophageal varices (EV) exacerbation.Methods: These risks were evaluated in 398 chronic hepatitis C patients without a history of HCC who achieved SVR after directacting antiviral agent and evaluated LSM at least twice during follow up. We defined liver cirrhosis and chronic hepatitis as LSM of ≥12 kPa and <12 kPa, respectively.Results: LSM was significantly correlated with serum fibrosis markers, such as Fib-4 index and Wisteria floribunda agglutinin-positive Mac-2 binding protein, at baseline and SVR at 24 weeks after treatment (SVR24). Five patients received preventive treatment of EV, but no EV bleeding occurred after SVR, and their LSM at baseline and SVR24 was significantly higher than that of other cirrhosis patients. The annual rate of HCC during the first 4 years was 1.5%. LSM in HCC patients tended to decrease after direct-acting antiviral agent therapies, but significantly higher than that of cirrhosis patients without HCC before and after treatment. Multivariate analysis identified LSM and alpha-fetoprotein at baseline and LSM at SVR24 as significant independent predictors of HCC. Conclusions:Evaluating LSM not only at baseline, but also SVR24, was found to be useful for the detection of advanced fibrosis patients at high risk of HCC occurrence and EV exacerbation. We recommend focused surveillance of HCC and EV for these patients.

show abstract

Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection

Abstract: The stage of stiffness graded by FibroScan has a good correlation with the liver fibrosis of resected liver specimens. It has the ability to diagnose fibrosis stage non-invasively.

Cited by 20 publications

References 30 publications

Estimation of Serum Interleukin-18 in Hepatitis C Patients in Zagazig University Hospitals

Estimation of Serum Interleukin-18 in Hepatitis C Patients in Zagazig University Hospitals

Liver stiffness in chronic hepatitis C virus infection

Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C

Contact Info

Product

Resources

About